No Data
HUAKANG BIOMED: 2024 INTERIM REPORT
Huakang Biomed (08622) announced its interim results, with a net loss of approximately 1.779 million yuan attributable to owners, a 22.27% year-on-year increase in the loss.
Huakang Biomed (08622) announced its 2024 interim performance, with revenue increasing by about 4% YoY to 11.9 million yuan...
HUAKANG BIOMED: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
HK stocks surge | Huakang Biomedical (08622) rose more than 40% in mid-day trading, planning to carry out online store and enzyme-based product trade business.
Huakang Biomedical (08622) rose more than 40% in intraday trading. As of press time, it has risen 31.63%, with a share price of HKD 0.129 and a turnover of HKD 0.401 million.
Huakang Biomed (08622.HK) plans to carry out enzyme-based product trade business involving online sales platforms and corporate-to-corporate trade operations of Enzyme Good Life Group (China) Co., Ltd.
On July 22, Gelonhui announced that Huakang Biomedical (08622.HK) plans to conduct enzyme-based product trading business ("new business activities") related to online sales platforms and enterprise-to-enterprise products for Haosheng Group (China) Co., Ltd. which is primarily engaged in the research and development, production, marketing and sales of in vitro diagnostic reagents, assisted reproductive supplies and equipment in China. The board of directors is actively exploring new business opportunities to bring higher returns to shareholders. Considering the sustained growth potential of enzyme-based products and e-commerce consumption in the domestic market in China in recent years, the directors believe that the implementation of new business activities will bring more opportunities for the group.
Huakang Biomedical Holdings Vice Chairman Yim Yang Chang Sells 31% Of HoldingNo Data
No Data
